Breast Cancer Liquid Biopsy

Breast Cancer Liquid Biopsy

Global Breast Cancer Liquid Biopsy Market to Reach $963.2 Million by 2030
In the changed post COVID-19 business landscape, the global market for Breast Cancer Liquid Biopsy estimated at US$106.7 Million in the year 2022, is projected to reach a revised size of US$963.2 Million by 2030, growing at aCAGR of 31.7% over the period 2022-2030. Reagent Kits, one of the segments analyzed in the report, is projected to record 32.4% CAGR and reach US$730.5 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Instruments segment is readjusted to a revised 31% CAGR for the next 8-year period.

The U.S. Market is Estimated at $31.2 Million, While China is Forecast to Grow at 30.4% CAGR
The Breast Cancer Liquid Biopsy market in the U.S. is estimated at US$31.2 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$161.4 Million by the year 2030 trailing a CAGR of 30.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 28.6% and 27.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 23.6% CAGR.

Select Competitors (Total 34 Featured) -

  • Biodesix, Inc.
  • Bio-Rad Laboratories
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina
  • Isogen Life Science B.V.
  • Menarini Silicon Biosystems
  • Myriad Genetics
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Breast Cancer Liquid Biopsy – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Breast Cancer Liquid Biopsy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 3: World Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 4: World 16-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 6: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 7: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 9: World Historic Review for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 10: World 16-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Risk Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 12: World Historic Review for Risk Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 13: World 16-Year Perspective for Risk Assessment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Reagent Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 15: World Historic Review for Reagent Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 16: World 16-Year Perspective for Reagent Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 18: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 19: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 21: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 22: World 16-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 24: World Historic Review for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 25: World 16-Year Perspective for Circulating Tumor Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 27: World Historic Review for Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 28: World 16-Year Perspective for Extracellular Vesicles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 30: World Historic Review for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 31: World 16-Year Perspective for Circulating Tumor DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
TABLE 32: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 33: USA Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 34: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 36: USA Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 37: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 39: USA Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 40: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
CANADA
TABLE 41: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 43: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 44: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 46: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 49: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
JAPAN
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
TABLE 50: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 51: Japan Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 52: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 53: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 55: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 58: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
CHINA
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
TABLE 59: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 60: China Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 61: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 63: China Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 64: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 65: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 66: China Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 67: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
EUROPE
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
TABLE 68: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 70: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
TABLE 71: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 73: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 76: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 79: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
FRANCE
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
TABLE 80: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 81: France Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 82: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 83: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 84: France Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 85: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 87: France Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 88: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
GERMANY
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
TABLE 89: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 90: Germany Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 91: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 94: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 95: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 97: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
ITALY
TABLE 98: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 99: Italy Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 100: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 101: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 103: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 106: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
UNITED KINGDOM
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
TABLE 107: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 108: UK Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 109: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 110: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 111: UK Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 112: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 113: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 114: UK Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 115: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
REST OF EUROPE
TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 117: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 118: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 120: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 121: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 123: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 124: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
ASIA-PACIFIC
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 126: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 127: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 129: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 130: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 132: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 133: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
REST OF WORLD
TABLE 134: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 135: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 136: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2023 & 2030
TABLE 137: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 138: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 139: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2023 & 2030
TABLE 140: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
TABLE 141: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
TABLE 142: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2023 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings